Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

20-02-2022 | ASCO GU 2022 | Conference coverage | Video

Olaparib plus abiraterone could be a new first-line treatment option for mCRPC

Fred Saad provides an overview of the PROpel study of olaparib plus abiraterone acetate for the first-line treatment of metastatic castration-resistant prostate cancer, and outlines the next steps (3:41).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Related content

18-02-2022 | ASCO GU 2022 | Conference coverage | News

Adding niraparib to abiraterone boosts mutated mCRPC outcomes

17-02-2022 | Prostate cancer | News

Health-related QoL data support olaparib use in HRR-mutated mCRPC

04-09-2020 | Prostate cancer | News

Rucaparib has ‘meaningful’ antitumor activity in BRCA-mutated mCRPC
  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.
Image Credits